Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 296

1.

Targeting androgen receptor to suppress macrophage-induced EMT and benign prostatic hyperplasia (BPH) development.

Lu T, Lin WJ, Izumi K, Wang X, Xu D, Fang LY, Li L, Jiang Q, Jin J, Chang C.

Mol Endocrinol. 2012 Oct;26(10):1707-15. Epub 2012 Aug 21.

2.

Targeting stromal androgen receptor suppresses prolactin-driven benign prostatic hyperplasia (BPH).

Lai KP, Huang CK, Fang LY, Izumi K, Lo CW, Wood R, Kindblom J, Yeh S, Chang C.

Mol Endocrinol. 2013 Oct;27(10):1617-31. doi: 10.1210/me.2013-1207. Epub 2013 Jul 26.

3.

Increased infiltrated macrophages in benign prostatic hyperplasia (BPH): role of stromal androgen receptor in macrophage-induced prostate stromal cell proliferation.

Wang X, Lin WJ, Izumi K, Jiang Q, Lai KP, Xu D, Fang LY, Lu T, Li L, Xia S, Chang C.

J Biol Chem. 2012 May 25;287(22):18376-85. doi: 10.1074/jbc.M112.355164. Epub 2012 Apr 2.

4.

Androgen receptor roles in the development of benign prostate hyperplasia.

Izumi K, Mizokami A, Lin WJ, Lai KP, Chang C.

Am J Pathol. 2013 Jun;182(6):1942-9. doi: 10.1016/j.ajpath.2013.02.028. Epub 2013 Apr 6. Review.

5.

Stromal androgen receptor roles in the development of normal prostate, benign prostate hyperplasia, and prostate cancer.

Wen S, Chang HC, Tian J, Shang Z, Niu Y, Chang C.

Am J Pathol. 2015 Feb;185(2):293-301. doi: 10.1016/j.ajpath.2014.10.012. Epub 2014 Nov 26. Review.

6.

Infiltrating macrophages promote prostate tumorigenesis via modulating androgen receptor-mediated CCL4-STAT3 signaling.

Fang LY, Izumi K, Lai KP, Liang L, Li L, Miyamoto H, Lin WJ, Chang C.

Cancer Res. 2013 Sep 15;73(18):5633-46. doi: 10.1158/0008-5472.CAN-12-3228. Epub 2013 Jul 22.

8.

Evidence of TGF-β1 mediated epithelial-mesenchymal transition in immortalized benign prostatic hyperplasia cells.

Hu S, Yu W, Lv TJ, Chang CS, Li X, Jin J.

Mol Membr Biol. 2014 Mar-May;31(2-3):103-10. doi: 10.3109/09687688.2014.894211. Epub 2014 Mar 20.

PMID:
24650126
9.

New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells.

Lai KP, Huang CK, Chang YJ, Chung CY, Yamashita S, Li L, Lee SO, Yeh S, Chang C.

Am J Pathol. 2013 Feb;182(2):460-73. doi: 10.1016/j.ajpath.2012.10.029. Epub 2012 Dec 4.

10.

Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells.

Zhu ML, Kyprianou N.

FASEB J. 2010 Mar;24(3):769-77. doi: 10.1096/fj.09-136994. Epub 2009 Nov 9.

11.

Epithelial-to-mesenchymal transition and estrogen receptor α mediated epithelial dedifferentiation mark the development of benign prostatic hyperplasia.

Shao R, Shi J, Liu H, Shi X, Du X, Klocker H, Lee C, Zhu Y, Zhang J.

Prostate. 2014 Jun;74(9):970-82. doi: 10.1002/pros.22814. Epub 2014 Apr 22.

PMID:
24752964
12.

Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer.

Jacob S, Nayak S, Fernandes G, Barai RS, Menon S, Chaudhari UK, Kholkute SD, Sachdeva G.

Endocr Relat Cancer. 2014 May 8;21(3):473-86. doi: 10.1530/ERC-13-0514. Print 2014 Jun.

13.

Sex steroid receptor expression and localization in benign prostatic hyperplasia varies with tissue compartment.

Nicholson TM, Sehgal PD, Drew SA, Huang W, Ricke WA.

Differentiation. 2013 Apr-Jun;85(4-5):140-9. doi: 10.1016/j.diff.2013.02.006. Epub 2013 Jun 20.

14.

NF-κB and androgen receptor variant expression correlate with human BPH progression.

Austin DC, Strand DW, Love HL, Franco OE, Jang A, Grabowska MM, Miller NL, Hameed O, Clark PE, Fowke JH, Matusik RJ, Jin RJ, Hayward SW.

Prostate. 2016 Apr;76(5):491-511. doi: 10.1002/pros.23140. Epub 2015 Dec 28.

15.

Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation.

Izumi K, Fang LY, Mizokami A, Namiki M, Li L, Lin WJ, Chang C.

EMBO Mol Med. 2013 Sep;5(9):1383-401. doi: 10.1002/emmm.201202367. Epub 2013 Aug 27.

16.

New therapy via targeting androgen receptor in monocytes/macrophages to battle atherosclerosis.

Huang CK, Pang H, Wang L, Niu Y, Luo J, Chang E, Sparks JD, Lee SO, Chang C.

Hypertension. 2014 Jun;63(6):1345-53. doi: 10.1161/HYPERTENSIONAHA.113.02804. Epub 2014 Mar 31.

17.

A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia.

Alonso-Magdalena P, Brössner C, Reiner A, Cheng G, Sugiyama N, Warner M, Gustafsson JA.

Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2859-63. doi: 10.1073/pnas.0812666106. Epub 2009 Feb 5.

18.

Transforming growth factor beta 1 and androgen receptors in prostate neoplasia.

Cardillo MR, Petrangeli E, Salvatori L, Ravenna L, Di Silverio F.

Anal Quant Cytol Histol. 2000 Oct;22(5):403-10.

PMID:
11064817
19.
20.

NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance.

Austin DC, Strand DW, Love HL, Franco OE, Grabowska MM, Miller NL, Hameed O, Clark PE, Matusik RJ, Jin RJ, Hayward SW.

Prostate. 2016 Aug;76(11):1004-18. doi: 10.1002/pros.23195. Epub 2016 May 16.

Supplemental Content

Support Center